Mayo Clinic recently launched a first-in-the-U.S. clinical test that helps patients who recently have been diagnosed with an inflammatory demyelinating disease (IDD) but may be unsure of the exact disorder.
The new test can distinguish other IDDs such as neuromyelitis optica, acute disseminated encephalomyelitis, optic neuritis, and transverse myelitis from multiple sclerosis (MS). The test uses live cells to identify patients who are positive for an antibody to myelin oligodendrocyte glycoprotein (or “MOG,” for short).
Discovery's Edge, Mayo Clinic's research magazine, recently highlighted how this type of test is developed.
The test was created by Mayo Clinic’s Neuroimmunology Laboratory within the Department of Laboratory Medicine and Pathology. The lab discovers antibodies and validates antibody tests to clarify differences among autoimmune diseases.
Read the full article to learn how the test was developed.